The engagement of a financial advisor by 180 Life Sciences to explore strategic alternatives typically indicates a proactive approach to enhance shareholder value, which can lead to positive market reactions. Potential strategic transactions such as a sale or merger often result in a short-term increase in stock price due to anticipated future growth or premium buyout offers. However, the lack of a definitive timeline and the company's statement that it will not disclose further developments unless a specific action is approved adds uncertainty to the outcome.